 "Sun Pharma, AstraZeneca seal distribution deal for heart drug")
"AZPIL and Sun Pharma have entered into a distribution services agreement in India for AstraZeneca's brand 'Axcer', a new brand of ticagrelor," Sun Pharma said in a BSE filing.
The company added that AZPIL already has a brand 'Brilinta' for ticagrelor molecule in India since 2012. Axcer is a drug used for the treatment of acute coronary syndrome (ACS).
Also Read
Sanjay Murdeshwar, MD, AstraZeneca Pharma India, said: "Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient's risk of another heart attack or cardiovascular-related death."
The company further said: "This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby, benefiting a greater number of ACS patients. It strengthens Sun Pharma's cardiology portfolio with the addition of a new patented therapy."
The Sun Pharma stock was trading at Rs 872 in the morning trade, down 0.79% from its previous close on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%